Biotest

Biotest EBIT per Share

Delisted

The EBIT per Share of Biotest (BIO.DE) as of Oct 13, 2026 is 2.44 EUR. In the previous year, EBIT per Share was 3.63 EUR — a change of -32.64% (lower).

EBIT per Share

2.44EUR

YoY

-32.64%

Last updated:

EBIT per Share of Biotest is 2024 2.44 EUR. EBIT per Share of Biotest was 2023 3.63 EUR. It decreases by -32.64% lower compared to the previous year.

The Biotest EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
0.24 EUR
Jan 1, 2020
-0.41 EUR
Jan 1, 2021
-1.25 EUR
Jan 1, 2022
-0.28 EUR
Jan 1, 2023
3.63 EUR
Jan 1, 2024
2.44 EUR
Jan 1, 2025 (e)
0.68 EUR
Jan 1, 2026 (e)
8.15 EUR
The Biotest EBIT per Share history
YEAREBIT per ShareYoY
est8.15EUR+1,094.06%
est0.68EUR-72.06%
2.44EUR-32.64%
3.63EUR-1,404.55%
-0.28EUR-77.73%
-1.25EUR+207.87%
-0.41EUR-267.02%
0.24EUR-9.37%
0.27EUR-211.52%
-0.24EUR-126.42%
0.91EUR-5.63%
0.96EUR-29.06%
1.36EUR-2.27%
1.39EUR+26.59%
1.10EUR+2.26%
1.07EUR-3.11%
1.11EUR-24.84%
1.47EUR-12.04%
1.68EUR+42.81%
1.17EUR+19.59%
0.98EUR+2.13%
0.96EUR—
Access this data via the Eulerpool API

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

EBIT per Share of Biotest is 2.44 EUR in 2024.

EBIT per Share of Biotest changed from 3.63 EUR to 2.44 EUR, representing a -32.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Biotest since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — Biotest

All Key Metrics — Biotest